Introduction
============

Esophageal cancer (EC) is currently the fifth most commonly diagnosed malignancy and the fourth leading cause of cancer deaths in China [@B1]. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) constitute two major histological types of EC. ESCC is the most common histological type in Chinese patients, accounting for 90% of all cases, whereas EAC is predominant in many western countries [@B2]. So far, the standard care for ESCC patients is curative esophagectomy, with or without chemoradiation therapy. Unfortunately, ESCC patients still show a poor five-year survival rate of \<30%, even after curative therapy and eventually developing rapid clinical progression [@B3], [@B4].Therefore, it is imperative to evaluate better prognostic factors, particularly serum predictive indicators, in ESCC patients.

Recent studies have demonstrated that a preoperative inflammatory response could be associated with tumor progression and metastasis and have a significant predictive and prognostic value in various types of cancers [@B5]-[@B8]. There is increasing recognition that the NLR, PLR, and MLR are three markers of systemic inflammation and the elevated values of them might lead to a poor prognosis in various solid tumors, including ESCC [@B9]-[@B12]. However, these three inflammatory factors only integrate two cells. SII, which based on peripheral neutrophil, platelet, and lymphocyte counts, was recently investigated as a novel prognostic marker [@B13]-[@B16]. And to our best knowledge, just few studies regarding SII in patients with surgically resected ESCC are available. Thus, we conducted the present study to investigate and verify the prognostic value of the SII for a larger cohort of patients with surgically resected ESCC.

Materials and Methods
=====================

Patients
--------

We retrospectively reviewed a database of medical records of 530 consecutive patients with surgically resected ESCC between 2005 and 2008 at the department of thoracic surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College. The inclusion criteria were as follows: (1) curative esophagectomy with R0 resection; (2) histologically confirmed ESCC; 3) preoperative serum laboratory results were obtained within five days before surgery. The exclusion criteria were as follows: (1) if patients received preoperative chemotherapy/radiotherapy; (2) if they had acute/chronic infection or (3) if they had hematological or autoimmune disease; (4) if they died during the perioperative period; (5) if they lacked detailed clinical information and follow-up information. Totally, 62 patients were excluded from this study. The whole enrollment process was clearly shown in Figure [1](#F1){ref-type="fig"}. Among these patients, 15 patients had infection, hematological or autoimmune disease; 12 patients had incomplete medical data; and 35 patients were lost to follow-up. Finally, a total of 468 patients were enrolled in the present study.

All included subjects provided written informed consent for the study protocol that was approved by the Ethical Committees of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College. Patients were followed up in the outpatient department every 3-6 months for the first two years after surgery and then annually. The follow-up included recording the medical history, physical examinations, chest computed tomography, and endoscopy (if necessary). The last follow-up was on July 9^th^ 2015. And in our study, the primary endpoints were 5-year OS and 5-year DFS.

Clinicopathological parameters
------------------------------

The clinicopathological parameters of the patients, including age, gender, smoking history, drinking history, tumor location, tumor differentiation grade, maximum tumor diameter, lymph node metastasis, TNM stage, operation time, and intraoperative blood loss, were obtained from the medical records. The pathological classification of the primary tumor, degree of lymph node metastasis, and presence of distant metastasis were assessed based on the American Joint Committee on Cancer staging manual (seventh edition) [@B17].

Blood sample analysis
---------------------

The laboratory data on preoperative CBC counts were retrospectively extracted from medical records. All these results were obtained within five days before surgery. CBC was measured using EDTA-treated blood and analyzed using an automated hematology analyzer XE-2100 (SYSMEX hematology analyzer; Medical Electronics, Kobe, Japan).

SII, NLR, PLR, and LMR evaluations
----------------------------------

Data on preoperative blood cell counts were retrospectively extracted from the medical records. White blood cell count data were analyzed in the general routine laboratory of our hospital within one week before surgery. We calculated the SII, NLR, PLR and MLR as follows: SII = platelet counts × neutrophil counts/lymphocyte counts, NLR = neutrophil counts/lymphocyte counts, PLR = platelet counts/lymphocyte counts, MLR = monocyte counts/lymphocyte counts.

Statistical analysis
--------------------

We used SPSS version 19.0 (IBM Corp., Armonk, NY, USA) to perform all statistical analyses. The Pearson Chi-square test was used to compare categorical variables. Multiple linear regression analyses were used to determine factors associated with SII, NLR, PLR, and MLR. We constructed the Receiver operated characteristics (ROC) curves to determine the cut-off values for SII, NLR, PLR, and MLR that yielded the joint maximum sensitivity and specificity. The Kaplan-Meier method was used for univariate analysis, and the difference between groups was assessed by the log-rank test. The Cox proportional hazard model was used for multivariate analysis, and hazard ratios (HRs) with 95% confidence intervals (CIs) were used to quantify the strength of the association between predictors and survival. A two-sided value of P \< 0.05 was considered statistically significant.

Results
=======

Patients characteristics
------------------------

The 468 patients in this study were 376 (80.3%) men and 92 (19.7%) women (Table [1](#T1){ref-type="table"}). The median age was 59.5 years (range, 36-81 years). The distribution of pathological stages was as follows: stage I, 46 (9.8%); stage II, 199 (42.6%); and stage III, 223 (47.6%). The mean follow-up duration was 49.1 ± 32.6 months (range, 3.2-114.5 months). At the end of the last follow-up, 270 (57.7%) patients had died.

The median preoperative SII, NLR, PLR, and MLR were 374.26 (range, 53.28-4748.19), 1.98 (range, 0.52-11.00), 109.66 (range, 32.79-418.52), and 0.148 (range, 0.003-0.854), respectively.

Selection of optimal cut-off values for SII, NLR, PLR and MLR
-------------------------------------------------------------

As shown in Figure [2](#F2){ref-type="fig"}, the AUC was 0.553, 0.540, 0.532, and 0.521 for SII, NLR, PLR, and MLR, respectively. The optimal cut-off values for the prediction of survival were 479.72 for SII, 2.27 for NLR, 117.07 for PLR and 0.19 for MLR. Consequently, patients were separately divided into two groups with high or low levels according to the optimal cut-off values. One hundred and forty-three patients (30.6%) had SII ≥ 479.72, 127 patients (27.1%) had NLR ≥ 2.27, 153 patients (32.7%) had PLR ≥ 117.07 and 165 (35.3%) patients had MLR ≥0.19.

Correlation between the clinicopathological parameters and SII, NLR, PLR, and MLR
---------------------------------------------------------------------------------

The relationship between the clinicopathological parameters and SII is shown in Table [1](#T1){ref-type="table"}. The preoperative SII were associated with gender (p = 0.005) and more intraoperative blood loss (p = 0.044) (Table [1](#T1){ref-type="table"}).

The relationship between the clinicopathological parameters and NLR, PLR, and MLR is shown in Table [2](#T2){ref-type="table"}. The preoperative NLR were associated with gender (p = 0.005), tumor length (p = 0.020), and T stage (p=0.010). The preoperative MLR were associated with tumor length (p = 0.010) and T stage (p=0.024) (Table [2](#T2){ref-type="table"}).

The prognostic value of SII, NLR, PLR, and MLR
----------------------------------------------

OS curves were plotted by the Kaplan-Meier method and compared using the log-rank test. High SII, NLR, PLR and MLR were associated with poor OS (p = 0.001, p = 0.033, and p = 0.027, respectively) (Figure [3](#F3){ref-type="fig"}A-[3](#F3){ref-type="fig"}C) and poor DFS (p \< 0.001, p = 0.034, and p = 0.024, respectively) (Figure [4](#F4){ref-type="fig"}A-[4](#F4){ref-type="fig"}C). However, no significant differences were found between MLR and patients\' OS (p = 0.104) (Figure [3](#F3){ref-type="fig"}D) and DFS (p = 0.093) (Figure [4](#F4){ref-type="fig"}D).

The prognostic value of SII was next investigated in stage I/II and stage III subgroup, separately. As shown in Figure [5](#F5){ref-type="fig"} and Figure [6](#F6){ref-type="fig"}, patients with SII ≥ 479.72 have worse OS in stage I/II subgroup (p = 0.002) (Figure [5](#F5){ref-type="fig"}A), but have no significant effects in stage III subgroup (p = 0.058) (Figure [6](#F6){ref-type="fig"}A). As for DFS, patients with SII ≥ 479.72 have worse DFS in stage I/II subgroup (p = 0.001) (Figure [5](#F5){ref-type="fig"}B) and stage III subgroup (p = 0.024) (Figure [6](#F6){ref-type="fig"}B).

Univariate and multivariate analyses
------------------------------------

Univariate analyses demonstrated that age, smoking history, T stage, lymph node metastasis, TNM stage, operation time, intraoperative blood loss, SII, NLR, PLR were significant risk factors for a poor prognosis for OS and DFS (Table [3](#T3){ref-type="table"}). To avoid multicollinearity, we conducted the multivariate analysis using four models separately. Each multivariate model included only one immune-inflammatory indicator (SII, NLR, PLR, or MLR). The results revealed age (P \< 0.001), TNM stage (P \< 0.001), operation time (P = 0.030), high SII levels (P = 0.001), high NLR (P = 0.013) and high PLR (P = 0.013) were found to be independently associated with a poor OS or DFS in the multivariate analysis (Table [4](#T4){ref-type="table"}).

Discussion
==========

In recent years, increasing evidence demonstrated that there is a strong association between systemic inflammation and cancer [@B18]-[@B20]. In the present study, we retrospectively analyzed a consecutive cohort of 468 ESCC patients who underwent curative esophagectomy with R0 resection in our center. To our best knowledge, the population size and the quality of follow-up of the present study were much better than other two similar studies [@B21], [@B22]. It was worth mentioning that our study focused on the prognostic value of the SII for both OS and DFS of the ESCC patients. Our result showed that a high SII was an independent predictor for both OS and DFS in patients with surgically resected ESCC, and by comparing the areas under the AUC curve, SII was superior to NLR, PLR, and MLR in terms of prognostic ability. We also found that high SII was associated with gender and intraoperative blood loss. Moreover, we divided the 468 patients into two different groups according to their TNM stage for further analysis. The subgroup results showed that SII retained prognostic significance in stage I-II ESCC subgroup (OS, DFS) and stage III ESCC subgroup (DFS).

Systemic inflammatory factors such as NLR, PLR and MLR have been found to be independent markers of prognosis in a variety of cancers, including ESCC [@B23]-[@B27]. Feng [@B24] *et al.* revealed that preoperative NLR and PLR were significant predictors of OS in patients with ESCC and that PLR was superior to NLR as a prognostic index. Nakamura *et al*. [@B25] and Yutong *et al*. [@B26] have suggested that an increased NLR is associated with tumor progression and poor survival in EC patients. Recently, a meta-analysis by Zhao *et al*. [@B28] showed that a higher PLR might be a significant predictive biomarker for EC patients. Hirahara *et al*. [@B23], [@B27] also demonstrated that a decreased LMR was an independent prognostic factor for OS in ESCC patients. SII, based on neutrophil, platelet, and lymphocyte counts, was shown to be an independent prognostic indicator for hepatocellular carcinoma, lung cancer, colorectal cancer, renal cancer, prostate cancer and gastric cancer patients [@B12], [@B13], [@B15], [@B29]-[@B31].

The mechanism by which high SII contributes to a poor prognosis in patients with solid cancer is still unclear. Several potential theories may be used to explain the prognostic values of SII. Firstly, neutrophils expand both in the tumor microenvironment and systemically, and are generally associated with poor prognosis in patients with solid cancers [@B32]. Neutrophils may activate endothelium and parenchymal cells to enhance circulating tumor cell adhesion for distant metastasis [@B33]. Neutrophilia is an inflammatory response that inhibits the immune system by suppressing the cytolytic activity of immune cells such as lymphocytes, activated T cells, and natural killer cells [@B34], [@B35]. Secondly, platelets may act as protective "cloaks" for circulating tumor cells (CTCs), shielding them from immune destruction. Platelet and endothelial cell adhesion proteins may also facilitate metastasis by augmenting tumor cell extravasation [@B36]. Thirdly, the importance of lymphocytes has been highlighted in several studies in which high TILs (tumor-infiltrating lymphocytes) has been associated with better response to cytotoxic treatment and prognosis in cancer patients [@B37], [@B38]. Lymphocytes can also secrete several cytokines, such as IFN-γ and TNF-α, to block tumor growth and improve the prognosis of cancer patients [@B39]. According to the above theories, SII should be a more objective marker that reflects the balance between host inflammatory and immune response status than all the other systemic inflammation indices such as NLR, PLR and MLR.

Our study had several limitations. First, our study may be limited by selection biases due to its single-centre, retrospective nature. Second, although our results showed that SII was an independent predictor of ESCC prognosis, the sensitivity and specificity of SII were not very high. Third, although our findings were in line with previous observations, it was not easy to verify our conclusions in another independent cohort due to the lack of standardized cutoff value for SII. The cutoff values for SII were different among these similar studies [@B21], [@B22], [@B40], [@B41]. So, we need perspective studies to find a proper cutoff value. Thus, multi-center collaborative prospective studies are warranted to confirm these preliminary results.

Conclusions
===========

The SII is an independent prognostic marker in patients with surgically resected ESCC, and the SII is superior to NLR, PLR and MLR in terms of prognostic ability. Moreover, SII retained prognostic significance in stage I-II ESCC subgroup (OS, DFS) and stage III ESCC subgroup (DFS).

This study was supported by the National Key R&D Program of China (2016YFC1303201, 2018YFC1312105), Beijing Nova Program (Z181100006218032), the CAMS Initiative for Innovative Medicine (2017-I2M-1-005), and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2017PT32001, PY2018B02).
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![The flowchart of the enrollment process](jcav10p3188g001){#F1}

![Receiver operating characteristic curve analysis for the optimal cut‐off value of SII, NLR, PLR and MLR. The areas under the curve for overall survival were 0.553, 0.540, 0.532, and 0.521 for SII, NLR, PLR and MLR, respectively.](jcav10p3188g002){#F2}
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![Kaplan-Meier OS curves (A) and DFS curves (B) for patients with TNM stage III disease](jcav10p3188g006){#F6}

###### 

The characteristics of the 468 patients grouped by SII

                                   Cases (number, %)   SII (number)   *P* value   
  -------------------------------- ------------------- -------------- ----------- -----------------
                                   468 (100)           \<479.72       ≥479.72     
  Gender                                                                          **0.005*^\*^***
  Male                             376 (80.3)          250            126         
  Female                           92 (19.7)           75             17          
  Age (years)                                                                     0.484
  ≤60                              247 (52.8)          168            79          
  \>60                             221 (47.2)          157            64          
  Smoking                                                                         0.546
  Ever                             209 (44.7)          142            67          
  Never                            259 (55.3)          183            76          
  Drinking                                                                        0.309
  Yes                              286 (61.1)          189            97          
  No                               182 (38.9)          136            46          
  Tumor length                                                                    0.261
  ≤3                               70 (15)             53             17          
  \>3                              398 (85)            272            126         
  Tumor location                                                                  0.455
  Upper                            62 (13.2)           47             15          
  Middle                           228 (48.7)          154            74          
  Lower                            178 (38.0)          124            54          
  Differentiation                                                                 0.841
  Well                             123 (26.3)          88             35          
  Moderate                         233 (49.8)          160            73          
  Poor                             112 (23.9)          77             35          
  T stage                                                                         0.147
  T1                               46 (9.8)            38             8           
  T2                               77 (16.5)           51             26          
  T3                               274 (58.5)          191            83          
  T4                               71 (15.2)           45             26          
  N stage                                                                         0.287
  N0                               238 (50.9)          166            72          
  N1                               129 (27.6)          91             38          
  N2                               74 (15.8)           46             28          
  N3                               27 (5.8)            22             5           
  TNM stage                                                                       0.169
  I                                46 (9.8)            37             9           
  II                               199 (42.5)          132            67          
  III                              223 (47.6)          156            67          
  Operation time (min)                                                            0.312
  \<200                            200 (42.9)          144            56          
  ≥200                             268 (57.1)          181            87          
  Intraoperative blood loss (ml)                                                  **0.044*^\*^***
  \<200                            220 (47.0)          163            47          
  ≥200                             248 (53.0)          162            86          

*^\*^P* less than 0.05 is significant.

SII = systemic immune-inflammation index

###### 

The characteristics of the 468 patients grouped by NLR, PLR and MLR

                                   Cases (number, %)   NLR (number)   *P* value   PLR (number)      *P* value   MLR (number)   *P* value                    
  -------------------------------- ------------------- -------------- ----------- ----------------- ----------- -------------- ----------- -------- ------- -----------------
                                   468 (100)           \<2.27         ≥2.27                         \<117.05    ≥117.05                    \<0.19   ≥0.19   
  Gender                                                                          **0.005*^\*^***                              0.172                        0.223
  Male                             376 (80.3)          266            126                           259         117                        238      138     
  Female                           92 (19.7)           75             17                            56          36                         65       27      
  Age (years)                                                                     0.349                                        0.490                        0.562
  ≤60                              247 (52.8)          175            72                            170         77                         163      84      
  \>60                             221 (47.2)          166            55                            145         76                         140      81      
  Smoking                                                                         0.917                                        0.428                        0.560
  Ever                             209 (44.7)          153            56                            145         64                         132      77      
  Never                            259 (55.3)          188            71                            170         89                         171      88      
  Drinking                                                                        0.287                                        0.615                        0.921
  Yes                              286 (61.1)          203            83                            195         91                         186      100     
  No                               182 (38.9)          138            44                            120         62                         117      65      
  Tumor length                                                                    **0.020*^\*^***                              0.128                        **0.010*^\*^***
  ≤3                               70 (15)             59             11                            53          17                         55       15      
  \>3                              398 (85)            282            116                           262         136                        248      150     
  Tumor location                                                                  0.670                                        0.922                        0.670
  Upper                            62 (13.2)           47             15                            43          19                         47       15      
  Middle                           228 (48.7)          162            66                            152         76                         162      66      
  Lower                            178 (38.0)          132            46                            120         58                         132      46      
  Differentiation                                                                 0.274                                        0.972                        0.260
  Well                             123 (26.3)          92             31                            82          41                         87       36      
  Moderate                         233 (49.8)          174            59                            158         75                         147      86      
  Poor                             112 (23.9)          75             37                            75          37                         69       43      
  T stage                                                                         **0.010*^\*^***                              0.727                        **0.024*^\*^***
  T1                               46 (9.8)            41             5                             32          14                         34       12      
  T2                               77 (16.5)           49             28                            54          23                         47       30      
  T3                               274 (58.5)          204            70                            185         89                         186      88      
  T4                               71 (15.2)           47             24                            44          27                         36       35      
  N stage                                                                         0.988                                        0.634                        0.398
  N0                               238 (50.9)          173            65                            156         82                         158      80      
  N1                               129 (27.6)          95             34                            91          38                         86       43      
  N2                               74 (15.8)           54             20                            48          26                         45       29      
  N3                               27 (5.8)            19             8                             20          7                          14       13      
  TNM stage                                                                       0.204                                        0.278                        0.228
  I                                46 (9.8)            38             8                             33          13                         35       11      
  II                               199 (42.5)          139            60                            126         73                         125      74      
  III                              223 (47.6)          164            59                            156         67                         143      80      
  Operation time (min)                                                            0.077                                        0.163                        0.696
  \<200                            200 (42.9)          153            47                            142         58                         132      68      
  ≥200                             268 (57.1)          188            80                            173         95                         171      97      
  Intraoperative blood loss (ml)                                                  0.253                                        1.000                        0.698
  \<200                            220 (47.0)          166            54                            148         72                         140      80      
  ≥200                             248 (53.0)          175            73                            167         81                         163      85      

*^\*^P* less than 0.05 is significant.

NLR = neutrophil-lymphocyte ratio; PLR = platelet-lymphocyte ratio; MLR = monocyte-lymphocyte ratio.

###### 

Univariate analysis with regard to OS in 468 patients with ESCC

                                                 OS                  DFS                                               
  ---------------------------------------------- ------------------- ------- ------------- ------------------- ------- -------------
  Gender (female, male)                          0.589               1.088   0.800-1.479   0.496               1.113   0.818-1.513
  Age (≤60, \>60)                                **0.001*^\*^***     1.517   1.192-1.927   **0.003*^\*^***     1.435   1.129-1.823
  Smoking (ever, never)                          **0.033*^\*^***     1.297   1.021-1.647   **0.025*^\*^***     1.313   1.034-1.668
  Drinking (yes, no)                             0.576               1.073   0.839-1.372   0.602               1.068   0.835-1.366
  Tumor size (cm) (≤3, \>3)                      0.139               1.307   0.917-1.865   0.105               1.341   0.940-1.913
  Tumor location (upper/middle, lower)           0.847               1.024   0.802-1.309   0.981               0.997   0.780-1.274
  Differentiation (well/moderate, poor)          0.408               1.122   0.854-1.473   0.316               1.150   0.876-1.509
  T stage (T1/T2, T3/T4)                         **0.004*^\*^***     1.525   1.143-2.036   **0.005*^\*^***     1.515   1.135-2.023
  Lymph node metastasis (negative, positive)     **\<0.001*^\*^***   2.136   1.672-2.728   **\<0.001*^\*^***   2.117   1.658-2.703
  TNM stage (I/II, III)                          **\<0.001*^\*^***   2.304   1.805-2.941   **\<0.001*^\*^***   2.310   1.811-2.948
  Operation time (min) (\<200, ≥200)             **0.049*^\*^***     1.278   1.001-1.632   **0.026*^\*^***     1.319   1.033-1.684
  Intraoperative blood loss (ml) (\<200, ≥200)   **0.013*^\*^***     1.357   1.066-1.728   **0.007*^\*^***     1.392   1.093-1.772
  SII (\<479.72, ≥479.72)                        **0.001*^\*^***     1.521   1.185-1.953   **\<0.001*^\*^***   1.583   1.233-2.032
  NLR (\<2.27, ≥2.27)                            **0.033*^\*^***     1.325   1.022-1.718   **0.035*^\*^***     1.323   1.020-1.715
  PLR (\<117.05, ≥117.05)                        **0.028*^\*^***     1.321   1.031-1.694   **0.024*^\*^***     1.331   1.038-1.706
  MLR (\<0.19, ≥0.19)                            0.104               1.225   0.959-1.566   0.094               1.234   0.965-1.576

*^\*^P* less than 0.05 is significant.

CI = confidence interval; OS = overall survival; HR = hazard ratio;

SII = systemic immune-inflammation index; NLR = neutrophil-lymphocyte ratio; PLR = platelet-lymphocyte ratio; MLR = monocyte-lymphocyte ratio

###### 

Multivariate analysis with regard to OS in 468 patients with ESCC

                                                 OS                  DFS                                                 
  ---------------------------------------------- ------------------- --------- ------------- ------------------- ------- -------------
  Age (≤60, \>60years)                           **\<0.001*^\*^***   1.606     1.260-2.046   **0.001*^\*^***     1.520   1.193-1.937
  Smoking (ever, never)                          0.163               1.191     0.932-1.523   0.176               1.183   0.928-1.508
  Differentiation (well/moderate, poor)          0.522               1.094     0.831-1.441   0.444               1.113   0.846-1.464
  T stage (T1/T2, T3/T4)                         0.761               1.055     0.746-1.494   0.801               1.046   0.739-1.480
  Lymph node metastasis (negative, positive)     0.221               1.295     0.856-1.957   0.276               1.258   0.832-1.901
  TNM stage (I/II, III)                          **\<0.001*^\*^***   2.330     1.825-2.975   **\<0.001*^\*^***   2.355   1.845-3.006
  Operation time (min) (\<200, ≥200)             **0.030*^\*^***     1.314     1.027-1.682   **0.012*^\*^***     1.372   1.307-2.162
  Intraoperative blood loss (ml) (\<200, ≥200)   0.231               1.166     0.907-1.498   0.180               1.186   0.924-2.105
  SII (\<479.72, ≥479.72)                        **\<0.001*^\*^***   1.604     1.247-2.063   **\<0.001*^\*^***   1.681   1.307-2.162
  NLR (\<2.27, ≥2.27)                            **0.013*^\*^***     1.396     1.074-1.815   **0.017*^\*^***     1.376   1.059-1.788
  PLR (\<117.05, ≥117.05)                        **0.013*^\*^***     1.370     1.067-1.758   **0.009*^\*^***     1.398   1.089-1.794
  MLR (\<0.19, ≥0.19)                            0.173               1\. 188   0.927-1.522   0.118               0.820   0.640-1.052

*^\*^P* less than 0.05 is significant.

CI = confidence interval; OS = overall survival; HR = hazard ratio;

SII = systemic immune-inflammation index; NLR = neutrophil-lymphocyte ratio; PLR = platelet-lymphocyte ratio; MLR = monocyte-lymphocyte ratio
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